P/E ratio for OptimizeRx (OPRX)
P/E ratio as of April 2024 (TTM): -12.3
According to OptimizeRx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -12.3415. At the end of 2022 the company had a P/E ratio of -26.7.
P/E ratio history for OptimizeRx from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -26.7 | -100.53% |
| 2021 | > 1000 | -2538.34% |
| 2020 | -208 | 343.9% |
| 2019 | -46.8 | -108.53% |
| 2018 | 549 | -2662% |
| 2017 | -21.4 | 32.15% |
| 2016 | -16.2 | -72.01% |
| 2015 | -57.9 | 145.28% |
| 2014 | -23.6 | -86.12% |
| 2013 | -170 | 541.51% |
| 2012 | -26.5 | 346.63% |
| 2011 | -5.93 | 8.54% |
| 2010 | -5.47 | 8.16% |
| 2009 | -5.05 | -52.39% |
| 2008 | -10.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Park City Group
PCYG | 39.2 | -417.63% | 🇺🇸 USA |
 LivePerson LPSN | -0.4383 | -96.45% | 🇺🇸 USA |
 Brightcove BCOV | -2.67 | -78.35% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.